Primary prevention of hepatitis B virus infection


KEY POINTS

  • Universal vaccination programs for hepatitis B have had a profound impact on reducing the incidence of hepatitis B virus (HBV) infection.
  • All infants should receive hepatitis B vaccination, with the first dose given at birth in the first 24 hours.
  • Infants born to mothers positive for hepatitis B surface antigen (HBsAg) should receive both hepatitis B immunoglobulin and the first dose of hepatitis B vaccine, administered concomitantly, within 12 hours of birth.
  • For HBsAg-positive women with high viral loads (> 200,000 IU/mL), consider use of antiviral therapy to further reduce the risk of mother-to-child transmission.
  • It is recommended that adolescents not vaccinated in childhood receive hepatitis B vaccines.
  • Individuals at risk of exposure should be vaccinated.
  • The Australian Immunisation handbook (update 2017) contains current recommendations and is an important resource for clinicians http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home

Print as PDF

  1. Australian Government. Australian Technical Advisory Group on Immunisation (ATAGI). The Australian Immunisation Handbook. Chapter 4.5. Hepatitis B. 10th (updated 22 June 2015) [internet]. Available at: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home (last accessed 24 June 2018).
  2. Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001;139:349–52.
  3. Goldstein ST, Fiore AE. Toward the global elimination of hepatitis B virus transmission. J Pediatr 2001;139:343–5.
  4. World Health Organization (WHO). Global routine vaccination coverage, 2015. Weekly Epidemiol Rec 2016;46:537-48.
  5. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 2007;132:1287–93.
  6. Ni Y-H, Chang M-H, Wu J-F, Hsu H-Y, Chen H-L, Chen D-S. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 2012;57:730–5.
  7. O’Sullivan BG, Gidding HF, Law M, Kaldor JM, Gilbert GL, Dore GJ. Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust NZ J Public Health 2004;28:212–6.
  8. Williams A. Reduction in the hepatitis B related burden of disease--measuring the success of universal immunisation programs. Commun Dis Intell Q Rep 2002;26:458–60.
  9. National HBV Testing Policy Expert Reference Committee. National hepatitis B testing policy. Darlinghurst: Australasian Society for HIV Medicine (ASHM), 2012.
  10. MacLachlan JH, Allard N, Towell V, Cowie BC. The burden of chronic hepatitis B virus infection in Australia, 2011. Aust NZ J Public Health 2013;37:416–22.
  11. Saari TN, American Academy of Pediatrics Committee on Infectious Diseases. Immunization of preterm and low birth weight infants. Pediatrics 2003;112:193–8.
  12. World Health Organization (WHO). The Global Advisory Committee on Vaccine Safety rejects association between hepatitis B vaccination and multiple sclerosis (MS). 2002. [internet]. Available at:  http://www.who.int/vaccine_safety/committee/topics/hepatitisb/ms/en/ (last accessed 26 June 2018).
  13. Duclos P. Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opin Drug Saf 2003;2:225–31.
  14. Ghebrehewet S, Baxter D, Falconer M, Paver K. Intradermal recombinant hepatitis B vaccination (IDRV) for non-responsive healthcare workers (HCWs). Human Vaccin 2008;4:280-5.
  15. He C, Nomura F, Itoga S, Isobe K, Nakai T. Prevalence of vaccine-induced escape mutants of hepatitis B virus in the adult population in China: a prospective study in 176 restaurant employees. J Gastroenterol Hepatol 2001;16:1373–7.
  16. Zheng Y, Lu Y, Ye Q, Xia Y, Zhou Y, Yao Q, et al. Should chronic hepatitis B mothers breastfeed? A meta analysis. BMC Public Health 2011;11(1):502.